Clinical trials: Cardiac Diseases
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Acute Kidney Injury
A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of AKI in subjects who are at high risk for AKI following cardiac surgery.
- Trial name
- NCT02610283
- Testing
- QPI-1002
- Where
- 36 sites in United States, Canada and 1 more
- Volunteers
- 341 people
- Sponsor
- Quark Pharmaceuticals
Myocardial Failure, Cardiac Failure
A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function
The purpose of this study is to investigate experimental medication BMS-986231 in patients with different levels of kidney function.
- Conditions
- Myocardial Failure, Cardiac Failure, Congestive Heart Failure, Kidney Failure
- Trial name
- NCT03332186
- Testing
- BMS-986231
- Where
- 3 sites in Czechia, Poland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
ST Elevation Myocardial Infarction
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI .
- Trial name
- NCT06147986
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Coronary Artery Disease, Multi Vessel Coronary Artery Disease
Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass
To assess safety and feasibility of a coronary bypass created with Vascudyne Acellular Tissue Engineered Vessel (ATEV) with External Support Structure (ESS) in patients requiring multi vessel coronary artery bypass grafting…
- Trial name
- VCAB-2 (NCT07078370)
- Testing
- ATEV with ESS
- Where
- 4 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Vascudyne, Inc.
Atrial Fibrillation
Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation
The purpose of this study is to assess the safety and function of the Aegis Sierra Ligation System in accessing and closing off the left atrial appendage (LAA) using a minimally invasive epicardial access approach.
- Trial name
- LASSO-AF (NCT02583178)
- Testing
- Aegis Sierra Ligation System
- Where
- 7 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- Aegis Medical Innovations
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Atrial Fibrillation (Paroxysmal), Paroxysmal AF
3-Dimensional Mapping System: The PULSTAR II Study
### Study Overview Study Name In simple terms, this study involves using a new device to treat a heart condition called "Paroxysmal Atrial Fibrillation." Sponsor The study is sponsored by a company called Shanghai Shangyang…
- Conditions
- Atrial Fibrillation (Paroxysmal), Paroxysmal AF, Pulsed Field Ablation
- Trial name
- PAF (NCT07586176)
- Testing
- Nanosecond pulsed electric field ablation system; Cardiac Pulsed Electric Field Ablation Catheter
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Shanghai Shangyang Medical Technology Co., Ltd.
ATRIAL FIBRILLATION, Syncope
BioMonitor Master Study
The BioMonitor is an implantable cardiac monitor used to automatically detect and record episodes of arrhythmia in patients with bradycardia, tachycardia, asystole and atrial fibrillation.
- Trial name
- BioMonitor (NCT01725568)
- Testing
- BioMonitor
- Where
- Germany
- Volunteers
- 152 people
- Sponsor
- Biotronik SE & Co. KG
Cardiovascular Diseases, Vascular Disease
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).
The DEScover Registry is designed to observe the results of using Drug Eluting Stents (DES) in patients in a real-world setting.
- Conditions
- Cardiovascular Diseases, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis
- Trial name
- DESCOVER (NCT00489320)
- Testing
- Cypher Stent
- Where
- United States
- Volunteers
- 7,759 people
- Sponsor
- Cordis US Corp.
Thrombosis
CASTLE (Clopidogrel And Serum Troponin Level Elevation)
Primary Objective: To test if 600 mg of clopidogrel loading dose administered ≥ 6 and ≤ 24 hours prior to PCI produce a greater decrease of periprocedural release of biochemical markers (CK, CK-MB, and troponin-T and/or I) of…
- Trial name
- CASTLE (NCT00716924)
- Testing
- Clopidogrel
- Where
- Mexico
- Volunteers
- 155 people
- Sponsor
- Sanofi
Congestive Heart Failure
Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure
The primary objective of this feasibility study is to provide clinical data to demonstrate the safety and activity of a concentrate of nucleated cells from bone marrow aspirate (BMAC) produced with the Harvest Bone Marrow…
- Trial name
- NCT01299324
- Testing
- BMAC infusion
- Where
- 3 sites in Germany, India and 1 more
- Volunteers
- 30 people
- Sponsor
- Harvest Technologies
Iron Deficiency, Chronic Heart Failure
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure
The purpose of this study is to confirm that treatment with IV ferric carboxymaltose improves exercise capacity, physical functioning and quality of life in patients with iron deficiency and chronic heart failure.
- Trial name
- EFFECT-HF (NCT01394562)
- Testing
- Ferinject (ferric carboxymaltose), Standard of Care
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Vifor Pharma
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
- Trial name
- PANACHE (NCT03098979)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 76 sites in United States, Austria and 10 more
- Volunteers
- 305 people
- Sponsor
- Bayer
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Aortic Valve Disease
Trifecta™ Durability Study
The Trifecta™ Durability Study was a multi-center, prospective, single-arm, post-market study conducted in Europe and Canada to collect long-term safety and performance data on the Trifecta™ valve.
- Trial name
- NCT01256710
- Testing
- Trifecta™ aortic bioprosthesis
- Where
- Germany
- Volunteers
- 1,151 people
- Sponsor
- Abbott Medical Devices
Paroxysmal Atrial Fibrillation
POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)
This is a post-market study collecting real-world clinical data on safety, effectiveness and procedural success of Boston Scientific Cardiac Cryoablation System (POLARx™ System)
- Trial name
- POLAR SMART (NCT05282823)
- Testing
- Boston Scientific Cardiac Cryoablation System
- Where
- 19 sites in Japan, South Korea
- Volunteers
- 295 people
- Sponsor
- Boston Scientific Corporation
Essential Hypertension With Stable Angina and Dyslipidemia
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.
- Trial name
- ALIVE (NCT02400775)
- Testing
- Azilsartan
- Where
- Japan
- Sponsor
- Takeda
Acute Coronary Syndrome
Fondaparinux EU-RMP (Adherence)
Fondaparinux, a synthetic and specific factor Xa inhibitor, was granted an ACS indication by Health Canada in March 2007 and by the EMEA in September 2007.
- Trial name
- NCT01406301
- Testing
- fondaparinux
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.